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INTRODUCTION
Donor lymphocyte infusion (DLI) is an effective thera-
peutic strategy for patients with chronic myeloid leukemia
(CML) who relapse after allogeneic hematopoietic trans-
plantation [1-6]. DLI induces cytogenetic and molecular
remissions in approximately 80% of CML patients who
relapse into cytogenetic or chronic phase but is less effective
in patients who relapse into accelerated or blastic phase
[5,6]. DLI can be complicated by the occurrence of acute
and chronic graft-versus-host disease (GVHD) in up to 60%
of patients. Pancytopenia and marrow aplasia occur primar-
ily in patients with hematologic relapse and low levels of
residual donor-derived cells [4]. The overall treatment-
related mortality associated with DLI is approximately 20%.
GVHD is the single most important cause of morbidity and
mortality after DLI, and strategies to decrease this occur-
rence are being actively explored [7].
Responses to DLI in CML are more common in patients
who develop GVHD. However, CML patients have often
achieved responses in the absence of clinical GVHD. This
observation has suggested that the graft-versus-leukemia
(GVL) effect can be separated from GVHD in this disease.
T cells are the principal mediators of both GVL and
GVHD. T-cell depletion is the most effective method for
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ABSTRACT
Donor lymphocyte infusions (DLIs) are an effective treatment for relapsed Chronic myeloid leukemia (CML) after
allogeneic transplantation but are limited by the occurrence of GVHD. CD8+ T lymphocytes are involved in the
pathogenesis of GVHD but may not be essential for the graft-versus-leukemia (GVL) effect in CML. We have
treated 26 CML patients with posttransplantation relapse with CD8-depleted DLI. Thirteen of 15 patients (87%)
who relapsed in early-phase CML achieved complete cytogenetic response, but only 1 of 11 who relapsed in
advanced-phase disease achieved complete response. Acute GVHD occurred in 2 patients (8%), and extensive
chronic GVHD occurred in 2 patients (11%). Treatment-related mortality was 11.5%. Responses were durable;
with a median follow-up of 4.2 years (1-7.5 years), only 1 responding patient relapsed (7%). CD8-depleted DLI was
equally effective and safe after unrelated donor transplants and sibling transplants. Cytogenetic clonal evolution at
the time of DLI was not predictive of treatment failure unless associated with hematologic criteria for disease accel-
eration. CD8 depletion is an effective method to separate GVL from GVHD for posttransplantation relapsed CML.
This strategy is associated with durable complete remissions and a low rate of complications and therefore merits
further investigation in larger-scale comparative trials.
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prevention of GVHD after allogeneic hematopoietic trans-
plantation, but it is also associated with a high risk of relapse
due to the loss of a GVL effect [8]. Selective depletion of
CD8+ cells from the donor marrow has been shown in a ran-
domized study to reduce the risk of GVHD with no increase
in the risk of relapse [9]. We have reported in a preliminary
study that selective depletion of CD8+ cells from DLI also
resulted in reduction of GVHD incidence without compro-
mising response [10]. However, it is unknown if remissions
after CD8-depleted DLI are durable and what factors pre-
dict outcome. In this study, we report our long-term experi-
ence with 26 patients with CML relapse after allogeneic
transplantation who were treated with CD8-depleted DLI.
PATIENTS AND METHODS
Eligibility Criteria
The 26 patients in this analysis all had relapsed CML
after allogeneic transplantation. These patients were treated
on a variety of protocols studying different methods of
CD8+ depletion. Patient accrual started in June 1993, and
the last patient was entered in April 1999. All patients
received CD8-depleted DLI on protocols approved by the
University of Texas, M.D. Anderson Cancer Center Institu-
tional Review Board, and all patients and donors gave a
written consent according to institutional policy.
Relapse was deﬁned as cytogenetic if the blood counts
were normal and as chronic, accelerated, or blastic phase
according to standard criteria [11,12]. Molecular tests were
not used for diagnosis of relapse. Patients were eligible for
DLI if they had more than 40% Philadelphia positive cells
in the marrow, if they had increasing CML burden on con-
secutive tests, or if they had recurrence of Philadelphia
positive cells after a T-cell–depleted transplantation.
Immunosuppressive therapy was discontinued at the time of
relapse for all patients. Patients developing GVHD or spon-
taneous remission were not eligible. Twelve patients were
given interferon prior to DLI. Interferon was given at 3 to
5 × 106 units, 3 times to daily as tolerable. Interferon was
given for a wide duration range (months to years). None of
the patients achieved major cytogenetic response prior to
DLI. Five patients, with both early- and advanced-stage
relapse, were also given interleukin-2 prior to DLI at 1.8 ×
106 units/m2 subcutaneously 5 times weekly.
Donor Lymphocyte Collection and CD8 Depletion
and Infusion
The donors of lymphocyte infusions were the original
related or unrelated donors of the hematopoietic allograft.
Two patients received granulocyte colony–stimulating factor
(G-CSF) mobilized mononuclear cells in an attempt to pre-
vent marrow aplasia. Donors underwent a single leuka-
pheresis using the Cobe Spectra continuous ﬂow blood cell
separator (Cobe, Lakewood, CO). Mononuclear cells were
isolated by density gradient centrifugation. Two methods of
CD8 depletion were explored in these patients: immuno-
magnetic separation using an anti-CD8 mouse monoclonal
antibody according to previously described techniques
(19 patients) [10] and a panning technique using anti-CD8
coated plastic flask (7 patients). T-cell depletion efficiency
and responses were similar for both methods.
The adequacy of T-cell depletion was assessed by ﬂow
cytometry and has been previously described [10]. Aliquots
of mononuclear cells obtained before and after CD8 deple-
tion were analyzed by 2-color ﬂow cytometry to determine
the relative number of CD3+, CD3+CD4+, and CD3+CD8+
lymphocyte subsets using conventional techniques. Cells
were stained with fluorochrome-conjugated monoclonal
antibodies for the speciﬁc antigens (Becton Dickinson, San
Jose, CA) and analyzed on a FACScan (Becton Dickinson,
Palo Alto, CA). The total number of CD4+ and CD8+ cells
was calculated by multiplying the percentage of the subset
by the total number of nucleated cells remaining after the
depletion procedure. Other cell populations (ie, B cells, NK
cells, etc) were not analyzed.
The CD8-depleted donor lymphocytes were infused
through a peripheral line over 10 to 15 minutes. The target
dose of the initial DLI was 0.5 × 108 mononuclear cells/kg.
(The actual doses and lymphocyte subsets infused are shown
in Table 1.) Patients not showing cytogenetic response in
16 weeks were eligible to receive a second DLI containing
1.0 × 108 mononuclear cells/kg. Patients were not eligible
for a second DLI if they developed grade III-IV acute
GVHD or steroid-resistant acute GVHD after the first
DLI. Patients with advanced-stage relapse could receive the
larger cell dose at the ﬁrst infusion at the discretion of the
attending physician. No immunosuppressive therapy was
administered for prevention of GVHD after DLI. Patients
who developed GVHD were treated according to the regu-
lar institutional protocols. Eight patients were given inter-
feron after DLI for control of high white counts as needed
until hematologic response. The treatment schedule was
similar to that given pre-DLI (see above). Six patients also
required hydroxyurea post-DLI for temporary control of
blood counts. Patients developing persistent pancytopenia
after DLI were eligible to receive donor stem cell support.
Study End Points
Patients were evaluated weekly for the ﬁrst 4 weeks and
quarterly thereafter by physical examination and blood
Table 1. Lymphocyte Subsets in Donor Lymphocyte Infusion*
Mononuclear Cells CD3+ Cells CD3+CD4+ Cells CD3+CD8+ Cells
Collected 10.7 × 109 (3.9-40) 5.7 × 109 (1.4-20.2) 4.0 × 109 (0.7-12.8) 2.0 × 109 (0.6-9.7)
After CD8 depletion 5.6 × 109 (2.5-28) 2.9 × 109 (1.2-11.8) 2.7 × 109 (1.1-11.1) 0.03 × 109 (0-0.04)
Infused† 0.71 × 108/kg (0.35-1.6) 41.5 × 106/kg (13.8-135.0) 39.8 × 106/kg (11.8-79.5) 0.3 × 106/kg (0-5.2)
*All parameters are presented as median (range).
†Infused doses are presented per kg recipient weight.
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counts. Bone marrow was aspirated before and at 3-month
intervals over the ﬁrst year after DLI or more frequently if
clinically indicated. The response criteria were those pro-
posed by Talpaz et al. [12] for biologic therapies for CML.
Complete hematologic remission was deﬁned as normaliza-
tion of peripheral blood counts with absence of peripheral
blasts, promyelocytes, or myelocytes, and disappearance of all
signs and symptoms of the disease. Complete cytogenetic
response was deﬁned as the absence of Philadelphia positive
metaphases in a sample containing at least 10 metaphases.
Cytogenetic analysis was performed using standard tech-
niques [13]. For the purpose of the study, response was
deﬁned as complete cytogenetic response. Molecular studies
were also performed on bone marrow samples for chimerism
and minimal residual disease assessment using previously
described techniques [14,15]. Acute and chronic GVHD were
staged and graded according to standard criteria [16,17].
Statistical Analysis
Overall survival (OS) was calculated from the time of
ﬁrst DLI until death from any cause or last follow-up. Disease-
free survival (DFS) was calculated from the time of docu-
mentation of complete cytogenetic response until cytoge-
netic relapse, death from any cause, or last follow-up. The
probabilities of OS, DFS, GVHD, and response rates were
calculated according to the method of Kaplan and Meier
[18]. The log-rank test was used to study the effects of cate-
gorical variables on survival curves. A stepwise logistic
regression analysis was used to assess the signiﬁcance of pre-
DLI factors in predicting outcome.
RESULTS
Patient Characteristics
The study group included 26 patients, 15 men and
11 women. The patient and disease characteristics are sum-
marized in Table 2. The median age at the time of DLI
was 41 years (range, 24-68 years). The donor was an HLA-
identical sibling in 20 patients and HLA-phenotypically
matched unrelated donor in 6 patients. The original trans-
plantation included a myeloablative conditioning regimen
in 21 patients (16 with total body irradiation [TBI]) and a
nonablative regimen in 5 patients. Eleven patients had
pan–T-cell or CD8+ T-cell depletion of the original graft.
Twelve patients had acute and/or chronic GVHD after
transplantation, but no patient had active GVHD at the
time of DLI. Relapse occurred at a median of 15 months
(range, 1-62 months) posttransplantation, and DLI was
administered at a median of 3 months (range, 0.5-95 months)
after documentation of relapse. Fifteen patients relapsed
in an early phase, either cytogenetic (8 patients) or chronic
(7 patients) phase. Eleven patients relapsed in advanced stage,
5 in accelerated phase and 6 in blast crisis. Eight of the
patients with hematologic criteria that defined early phase
had additional new cytogenetic abnormalities at the time of
relapse; all of them had TBI with the original transplantation.
CD8-Depletion Results and Infusion Characteristics
CD8 depletion resulted in a median depletion of 2.6 log
of CD8+ lymphocytes. The difference in levels of CD8
depletion with the immunomagnetic separation (2.5 log)
and with the panning technique (2.7 log) was not statistically
signiﬁcant. The median CD4+ cell dose infused with the ﬁrst
DLI was 39.8 × 106 cells/kg, and the median CD8+ dose was
0.3 × 106 cells/kg. Characteristics of unmanipulated and
infused cells are summarized in Table 1.
Response to DLI
Fourteen patients achieved complete cytogenetic
response (CR) following DLI. All responders also achieved
molecular remission, although this occurred at a median of
3 months (range, 0-6 months) after documentation of CR.
Response rate varied according to the stage of the disease at
the time of DLI. Fifteen patients were in early phase (cyto-
genetic or chronic phase) at the time of DLI. Thirteen of
these patients responded. The actuarial response rate was
87% (95% conﬁdence interval [CI], 79%-96%). Ten patients
responded after the ﬁrst DLI. Four received a second DLI,
and the fifth declined further treatment. Three of the
4 patients achieved CR after the second DLI. The median
time to CR was 117 days (range, 30-380 days) from the ﬁrst
DLI. The second DLI was administered in a median of
150 days (range, 95-280 days) after the ﬁrst.
Only 1 of the 11 patients who had advanced-stage
relapse responded. Response was achieved 30 days after
DLI. All 6 patients with an unrelated donor responded com-
pared to 8 of 20 recipients of sibling donor transplants, but
Table 2. Patient Characteristics











Time from transplantation to relapse, mo (range) 15 (1-62)
Time from relapse to DLI, mo (range) 3 (0.5-98)




T-cell depletion at transplantation
None 15
Pan–T-cell depletion 6
CD8+ T-cell depletion 5
Prior acute/chronic GVHD 8/4





*Eight patients also received hydroxyurea, and 5 patients received
interleukin-2.
†Including hydroxyurea and/or cytarabine.
‡DLI was administered after the failure of a second transplant from
the same donor.
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this difference relates to administration of DLI in early-
phase relapse in all 6 patients with unrelated donors and
only 9 of those with sibling donors. Those relapsing more
than 1 year after transplantation were more likely to
respond than those relapsing earlier, but this difference
again relates to the occurrence of most advanced-stage
relapses early in the course (Table 3). A multivariate analysis
identiﬁed disease status at DLI as the only variable predict-
ing response to DLI (P = .03).
Five patients were given DLI after nonmyeloablative
stem cell transplantation (NST). Because the response to
DLI or GVL biology may be different after NST, the
2 groups were analyzed separately. Relapse occurred earlier
after NST than after ablative conditioning, in a median
86 days compared to 548 days (P = .02). The other disease
characteristics outlined in Table 2 were not statistically dif-
ferent between the groups. Twelve of 13 patients relapsing
in early-stage disease after ablative transplant achieved CR
(actuarial response rate, 92%) compared to 1 of 2 recipients
of NST. OS was not signiﬁcantly different. The small num-
ber of NST recipients does not allow meaningful analysis.
Toxicity Related to DLI
Acute GVHD developed in 2 patients: 1 patient had
grade II and 1 patient had grade III. Acute GVHD occurred
23 and 19 days post-DLI and coincided with an early
response, documented a few days later, in both patients. Actu-
arial risk was 8% (95% CI, 3%-13%) for acute GVHD and
4% (95% CI, 0%-8%) for severe acute GVHD. Twenty-one
patients survived beyond 100 days. Chronic GVHD occurred
in 4 patients and was graded as limited in 2 patients and
extensive in the other 2 patients. Two patients had de novo
chronic GVHD occurring 110 and 137 days after DLI, at the
same time as documentation of response. The actuarial risk
was 22% (95% CI, 12%-32%) for chronic GVHD and 11%
(95% CI, 3%-19%) for extensive chronic GVHD. Chronic
GVHD was mild and responsive to therapy in all but
1 patient, who died of infection during treatment of chronic
GVHD. The other 3 patients recovered and were all off of
immunosuppressive treatment at the time of last follow-up.
There was no correlation between occurrence of GVHD
and CD4+ or CD8+ T-cell dose infused, donor type, having
received a T-cell–depleted graft, or prior history of GVHD,
but the low number of patients developing GVHD may not
have allowed identiﬁcation of predicting factors (Table 3).
Pancytopenia occurred in 8 of 14 responders, with an
actuarial risk of 41% (95% CI, 30%-52%). The nadir
occurred 88 days after the last DLI. Seventy-five percent
of those developing pancytopenia had more than 90%
Philadelphia positive metaphases in bone marrow aspirates
Table 3. Outcome After DLI by Patient and DLI Characteristics
Characteristic n CR, n (%) P GVHD*, n P 5-Year Survival, % P
Age, y
<40 13 9 (69) 2 68
>40 13 5 (38) NS 3 NS 44 NS
Sex
Male 15 8 (53) 3 53
Female 11 6 (55) NS 2 NS 57 NS
Disease stage
Early 15 13 (87) 4 87
Advanced 11 1 (9) .001 1 NS 12 .0003
Donor
Related 20 8 (40) 3 48
Unrelated 6 6 (100) .09 2 NS 83 NS
T depletion at transplantation
Yes 15 6 (40) 3 48
No 11 8 (73) NS 2 NS 64 NS
Prior GVHD*
Yes 12 5 (42) 1 58
No 14 9 (64) NS 4 NS 56 NS
Time to relapse
>1 y 13 11 (85) 3 77
<1 y 13 3 (23) .004 2 NS 32 .03
Clonal evolution†
No 7 5 (71) 2 71
Yes 8 8 (100) NS 2 NS 100 NS
CD4 dose
>40‡ 12 6 (50) 2 44
<40 14 8 (57) NS 3 NS 64 NS
CD8 dose
>0.3‡ 14 9 (64) 3 56
<0.3 12 5 (42) NS 2 NS 55 NS
*Acute or chronic GVHD.
†Only patients with early-stage relapse.
‡Doses in cells × 106/kg recipient weight.
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prior to DLI. Six patients recovered counts spontaneously
and 2 required stem cell infusion. One died after recovery
from persistent infection. Overall, treatment-related mortal-
ity occurred in 3 patients (11.5%): 1 patient died of acute
GVHD, 1 of chronic GVHD, and 1 from infection.
Survival and Outcome
The median follow-up of the 15 patients relapsing in
nontransformed phase was 4.2 years (range, 1-7.5 years).
Twelve of these patients are still alive; 2 patients have died
of infections and 1 from progressive glioblastoma multi-
forme without evidence of CML recurrence. The estimated
5-year survival rate is 76%. Nine of these 12 patients are
also disease-free: the DFS rate for these patients is 61% at
5 years after DLI. Two patients did not respond to DLI; and
only 1 of the responders relapsed, 18 months after DLI.
One of the nonresponders was salvaged with a second trans-
plant from a different donor, and the others are undergoing
other therapies.
Eleven patients relapsed into an advanced phase. Only
1 patient responded, but he died of acute GVHD. Two patients
remain alive and are undergoing other treatments. OS and
DFS rates are 12% and 0%, respectively. The difference in
survival between those relapsing in early phase and those
relapsing in advanced phase is highly signiﬁcant (Figure, P <
.001). Relapse beyond 1 year was also predictive for better
survival on univariate analysis (Table 3), but this is related to
the occurrence of advanced-stage relapses earlier after trans-
plantation. Disease status at DLI was the only factor predict-
ing survival identiﬁed by a multivariate analysis (P = .01).
Three patients underwent a second transplantation after
failure of DLI. One patient was in chronic phase, and
2 patients were in accelerated phase. The patient in chronic
phase achieved CR. One patient with accelerated phase died
in CR from toxicity. The other patient recovered with
leukemic hematopoiesis after a nonablative transplant.
DISCUSSION
DLI is an established and effective treatment for CML
relapse after allogeneic transplantation [1-6]. This strategy
provides direct evidence for the importance of the GVL
effect in curing leukemia with allogeneic transplantation.
The main toxic effect of DLI is GVHD, which occurs in
Overall survival and progression-free survival for all patients according to disease status at time of donor lymphocyte infusions.
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approximately 50% of patients and accounts for the majority
of nonrelapse deaths [5,6].
The effector cells that mediate GVL and GVHD have
not been completely deﬁned. T cells are the principal media-
tors of both processes, but different T-cell subsets, and even
different subsets within the CD4+ and CD8+ subsets, may be
involved in each. In some murine models of minor histocom-
patibility disparate, H-2–matched transplants, CD8+ lympho-
cytes have been shown to mediate both processes, whereas
CD4+ cells mediated GVL without inducing GVHD [19-21].
CD8+ cells have been implicated in the pathogenesis of
human GVHD, as well. CD4+ clones that can recognize and
lyse CML cells have been generated from bone marrow
donors [22]. These observations led to the study of selective
CD8 depletion of bone marrow allografts. CD8 depletion
resulted in reduction of the risk of GVHD with no increase
in relapse rate, which occurs after pan–T-cell depletion
[9,23,24]. Our preliminary report, as well as studies per-
formed by other groups, has shown that CD8+-depleted DLI
is effective in inducing remissions in posttransplantation
CML relapse and in reducing the risk of GVHD [10,24,25].
The patients in this study did receive a limited number of
CD8+ cells, and these cells may have expanded in vivo. We
cannot rule out that expansion of infused or preexisting
donor CD8+ lymphocytes, possibly with help provided by the
infused CD4 cells, contributed to the GVL effect seen after
CD8+-depleted DLI. Responses were not different with the
2 methods used for CD8 depletion, although the number of
patients may have been too small for comparison.
This report provides a long-term evaluation for assess-
ment of the durability of responses and factors for prediction
of outcome. Overall, the clinical outcomes after CD8+-
depleted DLI are very similar to those reported with unma-
nipulated DLI, with the major difference being reduced risk
for GVHD. The most important factor predicting response
was the status of disease at DLI. Eighty-seven percent of the
patients with early-stage relapse (cytogenetic or chronic
phase) responded, but only 20% of those in accelerated
phase and none of those in blastic crisis responded. Similar
responses have been reported with unmanipulated DLI [5,6].
A few patients were given interferon after DLI for tem-
porary control of counts. We cannot rule out that interferon
contributed to the response. However, interferon was dis-
continued as soon as a hematologic response occurred and
in most instances before cytogenetic responses. Cytogenetic
responses were durable in the absence of continuous inter-
feron treatment. Six patients were also given hydroxyurea
post-DLI. The 3 patients in early-stage relapse responded,
so it seems that hydroxyurea did not interfere with donor
lymphocyte function.
Acute GVHD occurred in 2 patients (actuarial risk,
8%), and extensive chronic GVHD occurred in 2 patients
(actuarial risk, 11%). These rates are significantly lower
than the rates of 40% to 60% and 30% to 40%, respectively,
reported with unmanipulated DLI [5,6].
A few studies reported that DLI from unrelated donors
is equally effective as DLI from sibling donors [26,27]. In
our series, all 6 patients receiving unrelated DLI responded;
1 died of GVHD and all the others are long-term disease-
free. CD8+-depleted unrelated DLI is therefore also as
effective as related DLI.
The kinetics of response were also similar to unmanipu-
lated DLI. Response occurred at a median of 4 months after
DLI and was preceded by pancytopenia in 41% of respon-
ders. Pancytopenia was related to the degree of remaining
donor hematopoiesis at the time of DLI. It has been suggested
in studies using unmanipulated DLI that DLI eliminates
host hematopoiesis by a potent graft-versus-hematopoietic
tissue effect and that when most hematopoiesis pre-DLI is
host-derived, DLI may result in marrow aplasia. The inci-
dence was therefore not expected to reduce with CD8
depletion [2,28]. However, this theory remains controver-
sial, and other groups have suggested that aplasia may also
involve failure of donor hematopoiesis by other undeﬁned
mechanisms [29].
Remissions after CD8+-depleted DLI have been durable
and have exceeded the duration of posttransplantation
remissions in most patients. Median follow-up was 4.2 years,
and the longest remission is now 7.5 years. Only 1 of the
responders relapsed (7%), similar to the 10% relapse rate
reported in other studies [5,6,30].
These observations suggest that CD8-depleted DLI
results in very similar outcomes to unmanipulated DLI. The
only difference is a reduction in GVHD risk. This differ-
ence may translate into a survival advantage, because there is
no increased risk of recurrence with a long follow-up. The
treatment-related mortality in this study was 11.5%, which
may be lower than the 20% to 30% reported in other stud-
ies [5,6,26]. This ﬁnding needs to be conﬁrmed in a larger
comparative study.
Other groups have investigated other ways to reduce the
risks of GVHD while retaining the beneﬁcial GVL effect.
The incidence of GVHD increases with the number of cells
infused, and there may be a different threshold for GVHD
and GVL. One approach is to administer escalating doses of
donor lymphocytes, starting with a relatively low dose and
escalating the dose on subsequent infusions given to nonre-
sponders at predetermined intervals [31-33]. Investigators at
the Hammersmith hospital [33] have compared an escalating
dose regimen, starting with 1 × 107 CD3+ cell/kg (1 × 106 for
DLI from unrelated donors), to a single larger-dose DLI
(median dose 1.5 × 108 CD3+ cells/kg). The escalating dose
regimen resulted in similar response rate but a lower inci-
dence of acute and chronic GVHD, despite the infusion of
an equivalent total number of lymphocytes with the multiple
infusions. In our series, CD8+ T-cell depletion resulted in
reduction of the total lymphocyte dose infused, and this may
partially explain the reduced incidence of GVHD. However,
the median CD3+ cell dose infused during initial DLI was
4.2 × 107, which is more than 4 times larger than the dose
used by the Hammersmith group with equivalent to lower
GVHD rates, suggesting a direct effect of CD8 depletion.
Infusion of unmanipulated 1 × 107 CD3+ cells/kg from the
group of donors in this study would have given a median of
6.6 × 106 CD4+ cells/kg and 3.4 × 106 CD8+ cells/kg. CD8
depletion allowed administration of about 6 times more
CD4+ lymphocytes with no increase in GVHD rates. Studies
using T-cell–depleted allografts with subsequent add-back of
lymphocytes have shown lower incidence of GVHD when
the lymphocytes are added later, after the transplantation
[34,35]. The lower incidence of GVHD with prolonged
administration of DLI over a few months may relate to the
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same phenomenon. The escalating dosage may induce toler-
ance to host tissues. With our approach, 3 of 14 ultimately
responding patients required a second infusion.
Another novel strategy for control of GVHD posttrans-
plantation is to transduce the donor cells with a suicide gene,
such as the herpes simplex virus thymidine kinase, which con-
fers sensitivity to ganciclovir. If the patient develops GVHD,
it can be abrogated by ganciclovir treatment [36,37]. Ideally,
cellular therapy should consist of disease-specific effectors
devoid of the potential to produce GVHD [22,38]. It is still
controversial if leukemia-specific targets exist and if
leukemia-specific cytotoxic T-lymphocytes (CTLs) can be
generated. Falkenburg et al. [22] reported a single case of a
patient with CML who was treated with ex vivo–generated
speciﬁc CTL. This technique is very demanding and still not
sufﬁciently advanced to allow large-scale clinical trials.
Another interesting observation in this study relates to
the significance of additional cytogenetic abnormalities in
predicting response to DLI. Cytogenetic clonal evolution is
considered a manifestation of disease progression and
indicative of accelerated phase [39]. The significance of
clonal evolution at relapse after allogeneic transplantation is
unknown. Cytogenetic abnormalities are common after
high-dose chemoradiotherapy and may not have the same
signif icance as spontaneous evolution.  Additional
cytogenetic abnormalities were observed at the time of
relapse in 8 of 15 patients who otherwise had early-phase
characteristics. In most patients, these were not the classical
abnormalities associated with clonal evolution in CML and
were associated with prior TBI. All but 1 patient responded
to DLI. Therefore, additional cytogenetic abnormalities in
the absence of other features of accelerated disease are not
predictive of failure to respond to DLI.
In conclusion, CD8-depleted DLI is an effective treat-
ment in early-phase CML relapse post-allotransplantation,
with durable remissions and relatively low incidence of
GVHD and treatment-related mortality. It is an effective
method to separate GVL from GVHD in this disease. CD8
depletion of DLI merits further study in larger-scale, com-
parative studies.
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